Molecular Mechanisms by which Statins Prevent and Reverse Hepatocellular Carcinoma

他汀类药物预防和逆转肝细胞癌的分子机制

基本信息

  • 批准号:
    10856787
  • 负责人:
  • 金额:
    $ 34.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-19 至 2027-08-31
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. HMG-CoA reductase (HMGCR) inhibitors, statins, show high potential in the prevention and treatment of cancer including HCC. We will investigate the mechanism by which statins fight against HCC and discovering the biomarkers to predict the therapeutic effects. Through our previously published work, we have used our conditional transgenic mouse models of HCC to identify a novel pathway that statins suppress MYC signaling to execute the anti-cancer properties. Also, we identified that MYC rewires metabolic pathways to promote fatty acid synthesis in addition to glucose and glutamine pathways. Inhibition of fatty acid synthesis by TOFA elicits dramatic regression of MYC driven tumors and the efficacy correlates to MYC level. Statin (e.g., Atorvastatin) blocks MYC phosphorylation in our MYC-driven HCC model and inhibit tumor initiation and progression (see our Preliminary Results). We hypothesize that the MYC pathway is suppressed by statins and this is a mechanism by which statins can prevent and treat HCC, both through direct anti-oncogene effects as well as by restoring immune surveillance. We will determine the mechanisms by which statins protect against HCC, we propose to 1) evaluate the anti-cancer efficacy of statins at different progression stages of MYC driven HCC (before MYC induction, early stage of tumorigenesis, late stage of HCC) and the condition of association with NASH; 2) identify specific metabolism pathways regulated by statin in MYC-HCC; 3) define the changes of immune system and specific effectors/cytokines influenced by statin; 4) discover the biomarkers that can predict the therapeutic effect of statin in prevention of HCC. Our team includes expertise in Medical Oncology, the MYC oncogene and Tumor Immunology (Felsher), Gastroenterology and HCC (Dhanasekaran) and Hepatology and liver disease (Verna and Brown). Dr. Verna and Dr. Brown are members of the Liver Cirrhosis Network (LCN) clinical program (RAF- CA-23-023) and are currently investigating the effect of lipid lowing medications (Statins) in patients with compensated NASH, ALD, cholestatic and cryptogenic cirrhosis. The LCN study provides us with a unique opportunity to identify mechanisms through use of our preclinical transgenic mouse model of HCC that can be evaluated using human clinical samples to available to us through the LCN. Our work will help identify lead to the identification of the mechanisms by which statins can block HCC as well as identify biomarkers that can predict when these agents are most likely to be useful in preventing HCC.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DEAN W FELSHER其他文献

DEAN W FELSHER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DEAN W FELSHER', 18)}}的其他基金

Targeting the MYC Pathway for the Treatment of Cancer
靶向 MYC 通路治疗癌症
  • 批准号:
    10463750
  • 财政年份:
    2020
  • 资助金额:
    $ 34.19万
  • 项目类别:
Targeting the MYC Pathway for the Treatment of Cancer
靶向 MYC 通路治疗癌症
  • 批准号:
    10693915
  • 财政年份:
    2020
  • 资助金额:
    $ 34.19万
  • 项目类别:
Targeting the MYC Pathway for the Treatment of Cancer
靶向 MYC 通路治疗癌症
  • 批准号:
    10256047
  • 财政年份:
    2020
  • 资助金额:
    $ 34.19万
  • 项目类别:
Targeting the MYC Pathway for the Treatment of Cancer
靶向 MYC 通路治疗癌症
  • 批准号:
    10053533
  • 财政年份:
    2020
  • 资助金额:
    $ 34.19万
  • 项目类别:
(PQ7)Multi-scale Analysis of Tumor Microenvironment Heterogeneity
(PQ7)肿瘤微环境异质性多尺度分析
  • 批准号:
    9378269
  • 财政年份:
    2017
  • 资助金额:
    $ 34.19万
  • 项目类别:
Cancer-Translational Nanotechnology Training Program (Cancer-TNT)
癌症转化纳米技术培训计划(Cancer-TNT)
  • 批准号:
    8934256
  • 财政年份:
    2015
  • 资助金额:
    $ 34.19万
  • 项目类别:
Cancer-Translational Nanotechnology Training Program (Cancer-TNT)
癌症转化纳米技术培训计划(Cancer-TNT)
  • 批准号:
    9443842
  • 财政年份:
    2015
  • 资助金额:
    $ 34.19万
  • 项目类别:
Cancer-Translational Nanotechnology Training Program (Cancer-TNT)
癌症转化纳米技术培训计划(Cancer-TNT)
  • 批准号:
    9321153
  • 财政年份:
    2015
  • 资助金额:
    $ 34.19万
  • 项目类别:
Prognostic Metabolic Signatures of Cancers Through Mass Spectrometry Imaging
通过质谱成像预测癌症的代谢特征
  • 批准号:
    8673796
  • 财政年份:
    2014
  • 资助金额:
    $ 34.19万
  • 项目类别:
Modeling and Predicting Therapeutic Resistance of Cancer
癌症治疗耐药性的建模和预测
  • 批准号:
    8766569
  • 财政年份:
    2014
  • 资助金额:
    $ 34.19万
  • 项目类别:

相似海外基金

経胸壁心臓超音波のBlood Speckle Imagingを用いた大動脈弓部病変評価の研究
经胸心脏超声血斑成像评价主动脉弓病变的研究
  • 批准号:
    24K10591
  • 财政年份:
    2024
  • 资助金额:
    $ 34.19万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A cluster randomized controlled trial to evaluate pharmacy-based health promotion program to improve blood pressure control in Bangladesh, India and Pakistan
一项整群随机对照试验,旨在评估孟加拉国、印度和巴基斯坦基于药房的健康促进计划,以改善血压控制
  • 批准号:
    23K24566
  • 财政年份:
    2024
  • 资助金额:
    $ 34.19万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Open Access Block Award 2024 - NHS Blood and Transplant NHSBT School
2024 年开放获取块奖 - NHS 血液和移植 NHSBT 学校
  • 批准号:
    EP/Z532551/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.19万
  • 项目类别:
    Research Grant
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
  • 批准号:
    MR/X032809/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.19万
  • 项目类别:
    Fellowship
A methodology to connect functionalized gonadal constructs to a chick embryo through mechanically induced blood vessels from an egg
一种通过鸡蛋机械诱导血管将功能化性腺结构连接到鸡胚胎的方法
  • 批准号:
    24K15741
  • 财政年份:
    2024
  • 资助金额:
    $ 34.19万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
STTR Phase I: A Completely Non-Toxic Blood Bag That Keeps Blood Healthier, Longer
STTR 第一阶段:完全无毒的血袋,使血液保持更健康、更长久
  • 批准号:
    2335363
  • 财政年份:
    2024
  • 资助金额:
    $ 34.19万
  • 项目类别:
    Standard Grant
How blood vessel stiffness regulates their growth and maintenance
血管硬度如何调节其生长和维持
  • 批准号:
    DE240101055
  • 财政年份:
    2024
  • 资助金额:
    $ 34.19万
  • 项目类别:
    Discovery Early Career Researcher Award
Engaging the over 50s to ensure the sustainability of our blood supply
让 50 多岁的人参与进来,确保我们血液供应的可持续性
  • 批准号:
    LP220200819
  • 财政年份:
    2024
  • 资助金额:
    $ 34.19万
  • 项目类别:
    Linkage Projects
Applying a Program Science approach for strengthening partnerships and advancing embedded research to optimize public health programming for HIV and sexually transmitted and blood-borne infections among criminalized populations in the Global South
应用计划科学方法来加强伙伴关系并推进嵌入式研究,以优化南半球犯罪人群中针对艾滋病毒、性传播和血源性感染的公共卫生规划
  • 批准号:
    502554
  • 财政年份:
    2024
  • 资助金额:
    $ 34.19万
  • 项目类别:
Designing and fabricating artificial blood cells for global shortages
设计和制造人造血细胞应对全球短缺
  • 批准号:
    DE240100236
  • 财政年份:
    2024
  • 资助金额:
    $ 34.19万
  • 项目类别:
    Discovery Early Career Researcher Award
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了